BioSpace News Archive

CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, announced acceptance of an oral presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Invivoscribe is pleased to announce that they have filed a supplemental Pre-Market Approval (sPMA) submission with the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) for the use of the LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s investigational drug quizartinib.

Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting.

Resolve Biosciences , the pioneer in Molecular Cartography™ technology, today announced it has secured a $71 million Series B financing.

Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors.

Softhread Inc. is pleased to announce an agreement with Clinical Consultants International (CCI), a wholly-owned subsidiary of Novo Integrated Sciences Inc., to offer a zero trust cybersecurity solution for smart and interconnected healthcare services consolidating its entrance into the rapidly evolving Health Care 4.0 ecosystem for health care delivery.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial intrahepatic cholestasis (PFIC) in a broad range of subtypes, age one to 17 years.

Devonian Health Group Inc. announced today that they will be participating in three Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss the latest investor presentation.

JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced that Duane Pinto, MD, MPH, has been appointed as Chief Medical Officer.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany.